Literature DB >> 23760524

Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes.

Diamantina Vasilatou1, Sotirios G Papageorgiou, George Dimitriadis, Vasiliki Pappa.   

Abstract

The term epigenetics refers to the heritable changes in gene expression that do not represent changes in DNA sequence. DNA methylation and histone modification are the best studied epigenetic mechanisms. However, microRNAs, which affect gene expression at the posttranscriptional level, should be considered as members of the epigenetic machinery too. Myelodysplastic syndromes (MDS) are clone disorders of the hematopoietic stem cell with increased risk of leukemic transformation. Over the years, increased number of studies indicates the role of epigenetic mechanisms, including microRNAs, in MDS pathogenesis and prognosis. Indeed, epigenetic therapy with demethylating agents has already been applied to MDS. In this review we summarize current knowledge on the role of epigenetic alterations in MDS pathogenesis and treatment.

Entities:  

Keywords:  DNA methylation; DNMTs; MDS; epigenetics; histone modification; microRNAs; polycomb system

Mesh:

Substances:

Year:  2013        PMID: 23760524      PMCID: PMC3857336          DOI: 10.4161/epi.24897

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  101 in total

1.  MicroRNA genes are transcribed by RNA polymerase II.

Authors:  Yoontae Lee; Minju Kim; Jinju Han; Kyu-Hyun Yeom; Sanghyuk Lee; Sung Hee Baek; V Narry Kim
Journal:  EMBO J       Date:  2004-09-16       Impact factor: 11.598

2.  A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis.

Authors:  Francesco Fazi; Alessandro Rosa; Alessandro Fatica; Vania Gelmetti; Maria Laura De Marchis; Clara Nervi; Irene Bozzoni
Journal:  Cell       Date:  2005-12-02       Impact factor: 41.582

3.  Diagnostic microRNAs in myelodysplastic syndrome.

Authors:  Begum Erdogan; Crystal Facey; Julianne Qualtieri; Jason Tedesco; Elizabeth Rinker; R Benjamin Isett; John Tobias; Donald A Baldwin; James E Thompson; Martin Carroll; Annette S Kim
Journal:  Exp Hematol       Date:  2011-06-15       Impact factor: 3.084

4.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.

Authors:  M Göttlicher; S Minucci; P Zhu; O H Krämer; A Schimpf; S Giavara; J P Sleeman; F Lo Coco; C Nervi; P G Pelicci; T Heinzel
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

5.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

Authors:  V M Richon; T W Sandhoff; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

6.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

7.  Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression.

Authors:  Giuseppe Zardo; Alberto Ciolfi; Laura Vian; Linda M Starnes; Monia Billi; Serena Racanicchi; Carmen Maresca; Francesco Fazi; Lorena Travaglini; Nelida Noguera; Marco Mancini; Mauro Nanni; Giuseppe Cimino; Francesco Lo-Coco; Francesco Grignani; Clara Nervi
Journal:  Blood       Date:  2012-02-10       Impact factor: 22.113

8.  TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes.

Authors:  Jieyu Wang; Xiaofei Ai; Robert Peter Gale; Zefeng Xu; Tiejun Qin; Liwei Fang; Hongli Zhang; Lijuan Pan; Naibo Hu; Yue Zhang; Zhijian Xiao
Journal:  Leuk Res       Date:  2012-10-23       Impact factor: 3.156

9.  Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.

Authors:  Shimin Zhao; Yan Lin; Wei Xu; Wenqing Jiang; Zhengyu Zha; Pu Wang; Wei Yu; Zhiqiang Li; Lingling Gong; Yingjie Peng; Jianping Ding; Qunying Lei; Kun-Liang Guan; Yue Xiong
Journal:  Science       Date:  2009-04-10       Impact factor: 47.728

10.  DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia.

Authors:  M Ewalt; N G Galili; M Mumtaz; M Churchill; S Rivera; F Borot; A Raza; S Mukherjee
Journal:  Blood Cancer J       Date:  2011-03-11       Impact factor: 11.037

View more
  10 in total

Review 1.  Diagnostic molecular techniques in haematology: recent advances.

Authors:  Aikaterini Koutsi; Elisavet-Christina Vervesou
Journal:  Ann Transl Med       Date:  2018-06

2.  Epigenetic regulation of miRNA-124 and multiple downstream targets is associated with treatment response in myeloid malignancies.

Authors:  Hongbin Liu; Phillip Pattie; Sahan Chandrasekara; Andrew Spencer; Anthony E Dear
Journal:  Oncol Lett       Date:  2016-07-25       Impact factor: 2.967

3.  Omics for Nurse Scientists Conducting Environmental Health Research.

Authors:  Lacey W Heinsberg; Yvette P Conley
Journal:  Annu Rev Nurs Res       Date:  2019-12-23

4.  Feedback signals in myelodysplastic syndromes: increased self-renewal of the malignant clone suppresses normal hematopoiesis.

Authors:  Thomas Walenda; Thomas Stiehl; Hanna Braun; Julia Fröbel; Anthony D Ho; Thomas Schroeder; Tamme W Goecke; Björn Rath; Ulrich Germing; Anna Marciniak-Czochra; Wolfgang Wagner
Journal:  PLoS Comput Biol       Date:  2014-04-24       Impact factor: 4.475

Review 5.  Potential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome.

Authors:  Ting Zhou; Peishuai Chen; Jian Gu; Alexander J R Bishop; Linda M Scott; Paul Hasty; Vivienne I Rebel
Journal:  Int J Mol Sci       Date:  2015-01-05       Impact factor: 5.923

6.  A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.

Authors:  Mónica Martínez-Fernández; Marta Dueñas; Andrew Feber; Cristina Segovia; Ramón García-Escudero; Carolina Rubio; Fernando F López-Calderón; Claudio Díaz-García; Felipe Villacampa; José Duarte; María J Gómez-Rodriguez; Daniel Castellano; José L Rodriguez-Peralto; Federico de la Rosa; Stephan Beck; Jesús M Paramio
Journal:  Oncotarget       Date:  2015-12-08

Review 7.  Digging deep into "dirty" drugs - modulation of the methylation machinery.

Authors:  Lisa Pleyer; Richard Greil
Journal:  Drug Metab Rev       Date:  2015-01-08       Impact factor: 4.518

8.  Discontinuation of the renin-angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes.

Authors:  George Pavlidis; Sotirios G Papageorgiou; Efthimia Bazani; Anthi Bouchla; Eirini Glezou; Konstantinos Gkontopoulos; Thomas Thomopoulos; Vasiliki Pappa; Demetrios V Vlahakos
Journal:  Ther Adv Hematol       Date:  2021-01-13

9.  Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients.

Authors:  Sandra Muntión; Teresa L Ramos; María Diez-Campelo; Beatriz Rosón; Luis Ignacio Sánchez-Abarca; Irena Misiewicz-Krzeminska; Silvia Preciado; María-Eugenia Sarasquete; Javier de Las Rivas; Marcos González; Fermín Sánchez-Guijo; María-Consuelo Del Cañizo
Journal:  PLoS One       Date:  2016-02-02       Impact factor: 3.240

Review 10.  MicroRNA-Related Polymorphisms in Infectious Diseases-Tiny Changes With a Huge Impact on Viral Infections and Potential Clinical Applications.

Authors:  Joel Henrique Ellwanger; Francis Maria Báo Zambra; Rafael Lima Guimarães; José Artur Bogo Chies
Journal:  Front Immunol       Date:  2018-06-14       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.